HC Wainwright Reaffirms Buy Rating for Sanara MedTech (NASDAQ:SMTI)

Sanara MedTech (NASDAQ:SMTI)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $36.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 73.08% from the stock’s current price. HC Wainwright also issued estimates for Sanara MedTech’s FY2025 earnings at $0.20 EPS.

Other analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Sanara MedTech from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $41.00.

Sanara MedTech Price Performance

Shares of SMTI stock opened at $20.80 on Monday. Sanara MedTech has a 12 month low of $18.90 and a 12 month high of $37.91. The stock has a 50-day moving average price of $22.83 and a 200 day moving average price of $27.22. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.34. The firm has a market cap of $185.12 million, a price-to-earnings ratio of -4.93 and a beta of 1.06.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.33. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. The business had revenue of $26.33 million for the quarter, compared to analyst estimates of $26.63 million. Research analysts expect that Sanara MedTech will post -1.1 EPS for the current year.

Hedge Funds Weigh In On Sanara MedTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its holdings in Sanara MedTech by 351.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after purchasing an additional 1,171 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after buying an additional 3,155 shares in the last quarter. Bank of America Corp DE raised its position in Sanara MedTech by 44.1% in the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after buying an additional 973 shares during the last quarter. Rhumbline Advisers raised its position in Sanara MedTech by 14.9% in the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after buying an additional 483 shares during the last quarter. Finally, Salem Investment Counselors Inc. lifted its stake in Sanara MedTech by 25.0% in the 4th quarter. Salem Investment Counselors Inc. now owns 10,897 shares of the company’s stock valued at $254,000 after acquiring an additional 2,182 shares in the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.